Clinical trials
Neuroendocrine Cancer clinical trials
Below are recruiting neuroendocrine cancer clinical trials, each written for real people, not researchers. We’re tracking 123 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07389512Recruiting
Pharmaceutical management in targeted radionuclide therapy study
This study is for adults who are getting targeted radionuclide therapy and have a pharmacist involved in managing their medicines. It looks at how the medication is handled to improve treatment safety and effectiveness.
BronAges 18 years+ - NCT07544654RecruitingPhase 3
Study comparing obrixtamig plus chemotherapy for advanced neuroendocrine cancer
This trial tests a new drug called obrixtamig combined with standard chemotherapy for advanced neuroendocrine cancer (a rare type of cancer). You'd receive one cycle of standard chemotherapy first, then be randomly assigned to either continue with the new drug plus chemotherapy or standard chemotherapy alone.
Scottsdale, ArizonaAges 18 years+ - NCT05556473RecruitingPhase 1
Tryptophan PET/CT scan study for different tumors
This early-phase study tests a special PET/CT scan using labeled tryptophan to help doctors see how different tumors behave. The goal is to learn whether this scan can better identify and measure cancers in the brain or elsewhere.
Detroit, MichiganAges 18 years+ - NCT07132645RecruitingEarly Phase 1
New scan for high-grade neuroendocrine cancer
This trial tests a new type of PET/CT scan called [68Ga]Ga-FAPI-04 to see if it can better detect high-grade neuroendocrine tumors. It is for patients whose standard scans show low uptake or who have aggressive tumor features.
Ann Arbor, MichiganAges 18 years+ - NCT06337760Recruiting
Young Adults with Digestive and Neuroendocrine Cancers
This trial studies treatments for young adults (ages 18-39) with cancers of the digestive system or neuroendocrine tumors. It aims to find better ways to help this age group, no matter the cancer stage or grade.
MilanAges 18–39 - NCT06503146RecruitingPhase 2
New imaging tracer for detecting various cancers
This trial tests a new imaging agent, [18F]FAPI-74, which might help detect certain cancers more clearly. The scan looks for a protein called fibroblast activation protein (FAP) that is often found in tumors. If you have one of the listed cancers and are about to start treatment, this study could help doctors see where the cancer is and how it responds to therapy.
Bethesda, MarylandAges 18–120 - NCT04104529Recruiting
Registry study for adults getting metabolic radiotherapy
This trial collects health and lab information from adults treated with metabolic radiotherapy in the nuclear medicine department. It may help doctors better understand how these treatments work for thyroid cancer, neuroendocrine tumors, or prostate cancer.
Bordeaux, AquitaineAges 18 years+ - NCT06577987RecruitingPhase 1
Study of CID-078 for advanced solid tumors
This trial tests an experimental drug called CID-078 for people with advanced solid tumors that have stopped responding to other treatments. It aims to find the right dose and see if the drug can shrink tumors.
Sarasota, FloridaAges 12 years+ - NCT06242119Recruiting
Testing a new PET scanner prototype
This study is testing a new type of PET scanner (called J-PET) to see if it works as well as current PET/CT machines. If you are already scheduled for a whole-body PET/CT scan, participating would mean your scan is done with this experimental scanner instead.
KrakowAges 18 years+ - NCT05160480Enrolling by invitation
Total-body PET scan using FDA-approved tracers for prostate or NET cancer
This pilot study tests a total-body PET scan with approved tracer medicines to help detect cancer spread in people with suspected metastatic prostate cancer or certain neuroendocrine tumors (NETs). You may be able to join if recent scans already suggest metastasis and you can safely complete the scan timing and positioning.
Sacramento, CaliforniaAges 18 years+ - NCT07517198RecruitingPhase 1
EXS74539 Study for Advanced Solid Tumors
This is an early-stage study testing a new cancer drug called EXS74539 to find the right dose and see how well it works in people with various advanced solid tumors. The drug may help patients whose cancers have stopped responding to standard treatments.
Los Angeles, CaliforniaAges 18 years+ - NCT03452774Recruiting
AI matches your cancer tests to possible treatment trials
This trial uses an AI system to help match people with certain cancer types and specific tumor test results (like gene or protein markers) to relevant clinical trials. It may help you and your doctor find studies that fit your cancer biology faster.
Birmingham, AlabamaAges Any age - NCT05691465RecruitingPhase 2
Radiation drug for metastatic prostate cancer with neuroendocrine cells
This Phase 2 study tests whether a radioactive medicine called lutetium Lu 177 dotatate is safe and effective for metastatic prostate cancer that has neuroendocrine features. It also checks whether patients’ scans show the cancer absorbs the drug (a requirement to start treatment).
Duarte, CaliforniaAges 18 years+ - NCT05804331Recruiting
Endoscopy treatment study for large upper stomach/throat lesions
This trial studies a specialized endoscopy procedure to remove larger abnormal growths in the upper digestive tract. It may help people whose lesion size and depth make certain removal techniques a better fit.
Sydney, New South WalesAges 18 years+ - NCT06479811RecruitingPhase 1
Radioactive drug for advanced neuroendocrine and other cancers
This trial tests a new radioactive drug, [212Pb]VMT-Alpha-NET, that targets a protein on certain cancer cells. It is for people with specific types of advanced cancers that have gotten worse and are not responding to standard treatments.
Bethesda, MarylandAges 18–120 - NCT05237934Recruiting
Study collects tissue samples and tracks neuroendocrine tumors
This study looks at neuroendocrine tumors by collecting tissue (when available) and tracking how the disease behaves over time. It may help researchers better understand these cancers, including rare cases of adrenocortical cancer.
Bethesda, MarylandAges 18–120 - NCT04119024RecruitingPhase 1
Gene-edited immune cells for advanced melanoma or solid tumors
This Phase 1 study tests a gene-modified immune cell treatment for advanced cancers that don’t have standard curative options. It may help by attacking cancer cells that show a specific marker called IL13Rα2 after patients receive “conditioning” chemotherapy to prepare the immune system.
Duarte, CaliforniaAges 18–75 - NCT06141369Recruiting
Personalized mRNA vaccine for advanced endocrine tumors
This trial tests a personalized mRNA vaccine made from your tumor's genetic information. It is for people with advanced endocrine tumors who have no standard treatment options left, and aims to help the immune system fight the cancer.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT02185443RecruitingPhase 2
SBRT radiation for liver metastases that can’t be surgically removed
This trial studies stereotactic body radiation therapy (high-precision radiation given in a few sessions) for liver metastases when surgery isn’t possible. It may help shrink or control tumors in the liver and delay progression in people whose cancer has not spread outside the liver (or only to areas treated with a curative plan).
São Paulo, São PauloAges 18 years+ - NCT07174583RecruitingPhase 1/Phase 2
Study of IDE849 for DLL3-positive cancers like SCLC
This trial tests a new drug called IDE849 for cancers that make a protein called DLL3, including small cell lung cancer and some neuroendocrine tumors. It is for people whose cancer has progressed after standard treatments, and may be given alone or combined with other drugs like durvalumab or IDE161.
Denver, ColoradoAges 18 years+ - NCT06814496RecruitingPhase 1/Phase 2
Radiation and immunotherapy combo for DLL3-positive cancers
This trial combines radiation with an immunotherapy drug called tarlatamab to treat cancers that make a protein called DLL3. The goal is to see if this combination works better than either treatment alone for people with certain types of lung cancer and other tumors that have not responded to prior therapy.
Tucson, ArizonaAges 18–99 - NCT05312671RecruitingPhase 2
Atezolizumab plus chemo for small cell bladder cancer
This trial studies whether a drug called atezolizumab combined with chemotherapy (etoposide and a platinum drug) can shrink or control small cell bladder cancer. It may help by boosting the immune system against the cancer while the chemotherapy treats fast-growing cancer cells.
Washington D.C., District of ColumbiaAges 18 years+ - NCT02174549RecruitingPhase 1/Phase 2
Testing a drug with liver artery treatment for liver-spread neuroendocrine cancer
This early-stage study tests a cancer drug called tirapazamine, given along with a liver artery procedure (embolization) to treat liver-dominant metastatic neuroendocrine tumors. It aims to find a safe dose and see whether the combination can better control tumor growth in the liver.
Palo Alto, CaliforniaAges 20–99 - NCT04268121RecruitingPhase 2
Neoadjuvant chemotherapy before surgery for certain digestive neuroendocrine cancers
This study looks at whether chemotherapy given before surgery improves how long patients live without the cancer coming back. It’s aimed at people with localized, poorly differentiated digestive neuroendocrine carcinoma with a higher growth rate marker.
AmiensAges 18 years+
Hear when a new Neuroendocrine Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for neuroendocrine cancer?
- Yes. Clin2 currently lists 123 recruiting neuroendocrine cancer studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a neuroendocrine cancer trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a neuroendocrine cancer trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.